A growing business generating $80M in annual revenue, with a forecast of $100M or more next year, isn’t shutting down anytime soon.
They have $17M in cash and access to bank loans of up to $21M, so there’s no immediate need for a capital raise. Despite constant speculation and posts from AT, a trader, and others over the past three months, no capital raise has occurred.
With FDA approval expected this year, Bubs has the potential to deliver multi-bagger returns from the current 10c level, imo. Time will tell, but I remain confident.
BUB Price at posting:
10.0¢ Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)